Journal: Immunity
Article Title: Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19
doi: 10.1016/j.immuni.2020.10.008
Figure Lengend Snippet: Serological Validation of COVID-19 Biomarkers (A) Overview of blood samples collection from cohort 3, including F (n = 40), S (n = 40), and M (n = 40) patients and H volunteers (n = 40). (B) The number of days between symptom onset and the sample collection with different time points. (C–G) Plasma levels of the indicated proteins from the samples of cohort 3 were detected via ELISA. Data points indicate the data of single patient that are presented as median with interquartile range (F, n = 40; S, n = 40; M, n = 40; H, n = 40). The center line within each box shows the median, and the top and bottom of each box represent the 75 th and 25 th percentile values, respectively. The upper and lower whiskers extend from the hinge to the largest and smallest value no further than 1.5 times the distance between the first and third quartiles, respectively. Data were analyzed by unpaired two-sided Welch’s t test. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001. See also and .
Article Snippet: Human Fetuin-B (FETUB) ELISA Kit , CUSABIO , Cat#CSB-EL008598HU.
Techniques: Biomarker Discovery, Clinical Proteomics, Enzyme-linked Immunosorbent Assay